Omexa

Omexa is a proprietary **transmucosal sublingual tablet formulation of sumatriptan** developed by Targia Pharmaceuticals for the treatment of **migraine**. In the provided public clinical-trial context, Omexa was evaluated in a randomized, open-label, crossover bioavailability study against commercial oral Imitrex, indicating that it is a **pharmaceutical reformulation** intended to deliver sumatriptan through the sublingual mucosa rather than as a conventional swallowed tablet. Pharmacologically, its active ingredient is sumatriptan, a **small-molecule serotonin receptor agonist** that exerts antimigraine activity primarily through agonism at **5-hydroxytryptamine receptor 1B and 1D**, leading to cranial vasoconstriction and inhibition of trigeminal neuropeptide release.

Brand names

Omexa

Other names

Omexa sumatriptan transmucosal sublingual tablet